Research Note

Immunocore has reported early data from a Phase 1/2 trial of brenetafusp combined with KIMMTRAK in metastatic uveal melanoma. Among 17 evaluable patients who received the combination as first-line treatment, the estimated overall survival rate was 88% after one year and 70% after two years. Median overall survival had not been reached after a median follow-up of 29 months, and 10 patients remained in the study.

Both medicines are designed to redirect T cells towards cancer cells, but they recognise different targets. KIMMTRAK targets gp100 and is already approved for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma. Brenetafusp is investigational and targets PRAME. Testing them together asks whether engaging both targets can improve tumour control beyond the established therapy.

The combination produced a 29% overall response rate, a median response duration of 24.1 months and a 71% disease-control rate. Median progression-free survival was 8.1 months. Cytokine release syndrome occurred in 77% of combination patients, although none of these events was grade 3 or 4. Overall, 38% had a grade 3 or 4 treatment-related adverse event, and no treatment-related event caused discontinuation or death.

These results are preliminary. The first-line group contained only 17 people, the trial was not randomised and there was no control arm against KIMMTRAK alone. Survival estimates can also change as follow-up continues. The data therefore support testing the combination, not a conclusion that it is better. Immunocore plans a randomised Phase 2/3 trial called DUET-UVEAL; that study will be the more useful test of added clinical benefit.

View Immunocore Holdings plc

Sources

Search companies & research

Search companies & research